CTDC had a nice breakout today, although I don’t see a clear play on it either way now.
COMV is right at resistance at $13. If it goes red it could be a nice short for 50 cents of downside.
NXTH died, like everything pumped or manipulated higher. There is no clear play on it now.
Disclosure: No positions in any stocks mentioned in this post. I have a disclosure policy and you can find all my disclaimers there as well; those disclosure & disclaimers are incorporated by reference into this post.
0 thoughts on “Watchlist for 10/28/2009”
MHR, short on red.
IGLD, short on red, but it has a huge gap I’m not sure of.
DRL, short on red, not a lot of downside.
PRKR, had it’s first down day, short on weakness.
Reminiscences of a Stock Operator by Edwin Lefevre.
What’s the difference between the book listed above, and the one by Jesse Livermore?
I found the one by Jesse on Michael Covell’s sight in PDF and read it, it was very good. I have went through your list and just noticed the one you have has a different author, just wondering.
It is the lightly fictionalized story of Jesse Livermore, written by Edwin Lefevre. In other words, Covel messed up; they are the same book.
SEC charges broker for creating false press releases.
Preston, you can get most free ebooks on almost any topic at gigapedia.info. Another site is Avaxsphere.
One version is available here
Reaper the SEC announced they are investigating APOL over the revenue recognition issue. Could be a mover tomorrow. Already down 17% after hours.
Looks like Left nailed another one.
QTM, DT, CQB pre-market.
Please save me from the horrid low-ADR NYSE stocks!
Merriman initiates Cyclacel Pharma (CYCC 0.97) with a Buy, based on its position as one of the few companies with a viable compound for the treatment of acute myeloid leukemia. Firm expects positive results in the near term from Cyclacel’s Phase II trial of sapacitabine for the treatment of AML in an elderly patient population
CYCC a good long above 1.15 or so.
“Merriman initiates Cyclacel Pharma (CYCC 0.97) with a Buy, based on its position as one of the few companies with a viable compound for the treatment of acute myeloid leukemia. Firm expects positive results in the near term from Cyclacel’s Phase II trial of sapacitabine for the treatment of AML in an elderly patient population”
Tanslation = They own a shit load of the stock and would like to sell into the buying of others.
qqqq got dumped to 41.6 in a flash
qqqq does a rebound. 42.1
pdfs rae cycc qtm wsii wbc mno 8%+
WSII decent enough chart. All the rest suck. Did no one check out my next post with my beautifully sung ode to NXTH?
09:13 Follow up on pre-mkt spike lower in equity futures
Would note that the heavy volume in Nasdaq (QQQQ) on the quick spike lower is not accompanied by the same kind of volume in the SPY and DIAThis could suggest the volume was triggered by some sort of “bad tick” in the Nasdaq futures, rather than reaction to any news. None of the Nasdaq 100 stocks are showing any dramatic declines in the past few minutes either.
PDFS and RAE both e/r last night.
sorry, RAE this AM
Michael, I thought it was great, I’ve been pressed for time this morning.
Your best post by far, creative and not a bad singing effort by you. And you did it without autotune, which is more than most Rap Artist can say these days.
stem: secondary news. 10m shares at 1.25
AMTD has shares of CYCC to borrow, I hope it goes to 2.00 in 15 minutes.
CQB a good buy at 17 if it can get there, still on low volume.
NXTH would’ve been a sick bounce play. It was the only play that could be made, really.
QCB broke HOD
NXTH is defying gravity.